Insmed CEO exits

iplexGeoffrey Allan, the chief executive at Insmed, has stepped down for health reasons, according to a company news release.

Allan has served as Insmed’s president, chief executive and chairman of the board since its inception in November 1999.

You can read the release here.   The release does not say what ails Allan.

The timing is not good for the company, which was making progress on another use for its drug Iplex. Click here to read in the New York Times about Lou Gehrig’s disease patients who are testing Iplex as a possible treatment.

iplexGeoffrey Allan, the chief executive at Insmed, has stepped down for health reasons, according to a company news release.

Allan has served as Insmed’s president, chief executive and chairman of the board since its inception in November 1999.

You can read the release here.   The release does not say what ails Allan.

The timing is not good for the company, which was making progress on another use for its drug Iplex. Click here to read in the New York Times about Lou Gehrig’s disease patients who are testing Iplex as a possible treatment.

This story is for our paid subscribers only. Please become one of the thousands of BizSense Pro readers today!

Your subscription has expired. Renew now by choosing a subscription below!

For more informaiton, head over to your profile.

Profile


SUBSCRIBE NOW

 — 

 — 

 — 

TERMS OF SERVICE:

ALL MEMBERSHIPS RENEW AUTOMATICALLY. YOU WILL BE CHARGED FOR A 1 YEAR MEMBERSHIP RENEWAL AT THE RATE IN EFFECT AT THAT TIME UNLESS YOU CANCEL YOUR MEMBERSHIP BY LOGGING IN OR BY CONTACTING [email protected].

ALL CHARGES FOR MONTHLY OR ANNUAL MEMBERSHIPS ARE NONREFUNDABLE.

EACH MEMBERSHIP WILL ONLY FUNCTION ON UP TO 3 MACHINES. ACCOUNTS ABUSING THAT LIMIT WILL BE DISCONTINUED.

FOR ASSISTANCE WITH YOUR MEMBERSHIP PLEASE EMAIL [email protected]




Return to Homepage

Subscribe
Notify of
guest

0 Comments
oldest
newest most voted
Inline Feedbacks
View all comments